Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker Corporation (Nasdaq: BRKR) will participate in the 40th annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The Company’s Chairman and CEO, Frank Laukien, along with Executive Vice President and CFO, Gerald Herman, will present on January 10 at 9:00 AM EST. A live audio webcast of this presentation will be accessible on the Investor Relations section of Bruker's website, with a replay available for 30 days post-event. Bruker focuses on high-performance scientific instruments, enhancing life sciences research and diagnostics.
Bruker has launched the JPK NanoWizard® V BioAFM, advancing atomic force microscopy for life sciences. This automated system integrates seamlessly with optical microscopes, facilitating rapid mechanobiological measurements from sub-molecular to cellular scales. Key features include enhanced speed, resolution, and user-friendly automation, promoting long-term experiments. Experts believe this innovation could greatly enhance the understanding of cellular processes. Bruker aims to leverage its decade-long experience in quantitative nanomechanics to empower researchers in the biomedical field.
Bruker Corporation (Nasdaq: BRKR) has completed a private placement of 10-year senior notes totaling
Bruker Corporation (Nasdaq: BRKR) announced its CE-IVD marked FluoroType® SARS-CoV-2 varID Q PCR assay, capable of detecting all major variants of SARS-CoV-2, including Omicron (B.1.1.529). The assay identifies key S-gene mutations associated with Omicron and provides viral load results in less than 4 hours. It is validated for use with the FluoroCycler® XT thermocycler and supports automated extraction via the GenoXtract® fleXT system. Bruker’s other SARS-CoV-2 assays are also expected to detect the Omicron variant.
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of MOLECUBES NV, enhancing its nuclear molecular imaging (NMI) capabilities. This strategic move aims to expand Bruker's preclinical imaging portfolio with the modular benchtop CUBES™ systems, expected to accelerate NMI adoption in medical and biopharma sectors. MOLECUBES generated approximately Euro 5 million in FY 2020 revenue and will operate within Bruker's BioSpin division, aiming for synergies in research and development.
Bruker Corporation (Nasdaq: BRKR) has announced significant advancements in 4D proteomics workflows, highlighted during the HUPO Reconnect 2021 virtual congress. They introduced a co-marketing agreement with Cellenion for the innovative cellenONE® system, enhancing automation in single-cell proteomics. Additionally, the partnership with Seer enables unprecedented detection of over 3,000 protein groups from human plasma using the Proteograph™ Product Suite. Bruker also expanded its collaboration with PreOmics to showcase the BeatBox™ technology for efficient tissue homogenization, improving proteomic analysis speed and yield.
Bruker Corporation (Nasdaq: BRKR) has announced a quarterly cash dividend of
The Board also approved an increase in the annual cash dividend from
Bruker Corporation (Nasdaq: BRKR) will take part in the 2021 Jefferies London Healthcare Conference on November 16, 2021, at 12:20 PM GMT. Gerald Herman, Executive Vice President & Chief Financial Officer, will lead an analyst-moderated Q&A session. A live audio webcast can be accessed via the company's Investor Relations website at https://ir.bruker.com. A replay will be available for 30 days post-event in the 'Events & Presentations' section.
Bruker Corporation (Nasdaq: BRKR) announced major advancements in its mass spectrometry capabilities at the 69th ASMS meeting in Philadelphia. The new CCS-enabled technologies for the timsTOF Pro 2, timsTOF fleX, and timsTOF SCP systems enhance proteomics workflows with rapid, high-sensitivity analysis. Key features include the identification of over 8,000 cell lysate proteins, a new OligoQuest software for RNA analysis, and the SCiLS autopilot for automated mass spectrometry imaging. These innovations aim to improve proteomics research, particularly in cancer biology and therapeutic development.
Bruker Corporation (Nasdaq: BRKR) reported Q3 2021 revenues of $608.9 million, a 19.1% increase year-over-year, with organic growth of 17.8%. GAAP EPS rose 63% to $0.57, while non-GAAP EPS increased 50% to $0.63. Operating income stood at $113.2 million with margins improving to 18.6%. For the first nine months, revenues totaled $1,734.4 million, an increase of 27.5%. The company raised its FY 2021 guidance, expecting revenue growth of 19.5%-20.5% and non-GAAP EPS between $2.05 and $2.09.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
